Can Fite Net Income Over Time
| CANF Stock | USD 4.21 0.10 2.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Can Fite Performance and Can Fite Correlation. Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Can Fite Biopharma and related stocks such as Kazia Therapeutics, CNS Pharmaceuticals, and Clearmind Medicine Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| CNSP | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14.5 M) | (15.3 M) | (18.9 M) | (14.9 M) | (13.4 M) | (14 M) |
| CMND | (33.2 K) | (33.2 K) | (33.2 K) | (33.2 K) | (46.9 K) | (24.2 K) | (6.5 K) | (194.5 K) | (105.3 K) | (233.2 K) | (3.7 M) | (9.9 M) | (11.9 M) | (7.3 M) | (5.4 M) | (4.9 M) | (5.1 M) |
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| OGEN | (1.7 M) | (7.7 M) | (13.1 M) | (16.1 M) | (5.8 M) | (11.7 M) | (7 M) | (6.7 M) | (9.9 M) | (15.6 M) | (26.4 M) | (15.7 M) | (14.3 M) | (20.7 M) | (10.6 M) | (9.5 M) | (10 M) |
| BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (10.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (5.7 M) | (5.2 M) | (5.4 M) |
| JAGX | (25.5 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (16.3 M) | (14.7 M) | (22 M) | (32.1 M) | (38.5 M) | (33.8 M) | (52.6 M) | (47.5 M) | (41.3 M) | (38.5 M) | (34.6 M) | (36.4 M) |
| CLDI | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (10.9 M) | (25.4 M) | (29.2 M) | (22.1 M) | (19.9 M) | (20.9 M) |
Can Fite Biopharma and related stocks such as Kazia Therapeutics, CNS Pharmaceuticals, and Clearmind Medicine Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Can Fite Biopharma financial statement analysis. It represents the amount of money remaining after all of Can Fite Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Can Fite Biopharma | CANF |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 26 Ben Gurion |
| Exchange | NYSE MKT Exchange |
USD 4.21
Check out Can Fite Performance and Can Fite Correlation. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Can Fite technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.